Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 3 Clinical |
The First Affiliated Hospital Of Soochow University |
Leukemia; Multiple Myeloma |
Details
|
ABBV-383 |
TNB-383B; ABBV-383 |
Phase 3 Clinical |
Teneobio Inc, Abbvie Inc |
Multiple Myeloma |
Details
|
Alnuctamab |
CC-93269; EM-901; BMS-986349 |
Phase 3 Clinical |
Engmab Ag |
Multiple Myeloma |
Details
|
BCMA CAR-T Cells (Pregene) |
PRG-1801 |
Phase 2 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anitocabtagene autoleucel |
CART-ddBCMA; Kite-772 |
Phase 2 Clinical |
Arcellx Inc |
Multiple Myeloma |
Details
|
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) |
BCMA-CART; HR003 |
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Lymphoma, B-Cell; Multiple Myeloma; Lymphoma, Non-Hodgkin |
Details
|
BCMA CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell |
Details
|
C-CAR088 |
C-CAR088 |
Phase 2 Clinical |
|
Multiple Myeloma |
Details
|
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) |
Descartes-08 |
Phase 2 Clinical |
Cartesian Therapeutics Inc |
Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
Orvacabtagene autoleucel |
ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 |
Phase 2 Clinical |
Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc |
Multiple Myeloma |
Details
|
GC-012F |
GC-012F; GC012F |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin |
Details
|
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) |
|
Phase 2 Clinical |
Asclepius Technology Company Group |
Multiple Myeloma |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
KQ-2003 |
KQ2003; KQ-2003 |
Phase 2 Clinical |
Shanghai Keqi Pharmaceutical Technology Co Ltd |
Solid tumours; Multiple Myeloma; POEMS Syndrome |
Details
|
HDP-101 |
HDP-101; HDP101-ATAC |
Phase 2 Clinical |
Heidelberg |
Paraproteinemias; Multiple Myeloma |
Details
|
REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
|
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech) |
|
Phase 2 Clinical |
Essen Biotech |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Myositis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic |
Details
|
Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences) |
|
Phase 2 Clinical |
Shahid Beheshti University Of Medical Sciences |
Multiple Myeloma |
Details
|
IBI-3003 |
IBI3003; IBI-3003 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) |
|
Phase 2 Clinical |
Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 2 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Multiple Myeloma |
Details
|
MBS-314 |
MBS-314 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Multiple Myeloma |
Details
|
SAR445514 |
SAR445514; SAR-445514; IPH6401/SAR514 |
Phase 2 Clinical |
Sanofi |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
CART-BCMA(Simnova) |
SNC-102(Simnova); SNC102(Simnova) |
Phase 2 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
CAR-BCMA(Sheba Medical Center) |
|
Phase 2 Clinical |
Sheba Medical Center, Israel |
Multiple Myeloma |
Details
|
Humanized CART Directed Against BCMA |
ARI-0002h |
Phase 2 Clinical |
Instituto De Salud Carlos Iii |
Multiple Myeloma |
Details
|
Descartes-11 |
Descartes-11; Descartes-011 |
Phase 2 Clinical |
Cartesian Therapeutics Inc |
Multiple Myeloma |
Details
|
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Multiple Myeloma |
Details
|
CM-336(Connaught Biomedical Technology) |
CM-336 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
PHE-885 |
PHE-885 |
Phase 2 Clinical |
Novartis Pharma Ag |
Hematologic Neoplasms; Multiple Myeloma |
Details
|
ALLO-605 |
ALLO-605; ALLO605 |
Phase 2 Clinical |
Cellectis Sa |
Multiple Myeloma |
Details
|
EMB-06 |
EMB-06; EMB06 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Multiple Myeloma |
Details
|
NXC-201 |
HBI-0101; NXC-201 |
Phase 2 Clinical |
Immix Biopharma Inc, Hadassah Medical Organization |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Neoplasms; Multiple Myeloma |
Details
|
BCMA TriTAC |
HPN-217 |
Phase 1 Clinical |
Harpoon Therapeutics, Abbvie Inc |
Multiple Myeloma |
Details
|
ACTR 087/SEA BCMA combination therapy |
|
Phase 1 Clinical |
Unum Therapeutics Inc |
Multiple Myeloma |
Details
|
Motacabtagene lurevgedleucel |
CTX-120 |
Phase 1 Clinical |
Crispr Therapeutics Ag |
Multiple Myeloma |
Details
|
AUTO-2 |
AUTO-2; SUB-96123 |
Phase 1 Clinical |
Autolus |
Multiple Myeloma |
Details
|
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
POEMS Syndrome |
Details
|
bb-21217 |
bb-21217 |
Phase 1 Clinical |
Bluebird Bio Inc, Bristol-Myers Squibb Company |
Multiple Myeloma |
Details
|
AMG-224 |
AMG-224 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
Ispectamab debotansine |
CC-99712; BMS-986352; SP-8919 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
WVT-078(Novartis Pharma) |
WVT-078 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
Pacanalotamab |
AMG-420; BI-836909 |
Phase 1 Clinical |
Micromet Inc |
Multiple Myeloma |
Details
|
ALLO-715 |
ALLO-715 |
Phase 1 Clinical |
Cellectis Sa |
Multiple Myeloma |
Details
|
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 1 Clinical |
The First Affiliated Hospital Of Nanchang University |
Multiple Myeloma |
Details
|
Pavurutamab |
AMG-701 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
CART-BCMA |
MTV-273; CART-BCMA |
Phase 1 Clinical |
University Of Pennsylvania |
Rejection of renal transplantation; Renal Insufficiency; Multiple Myeloma; Kidney Failure, Chronic |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Multiple Myeloma; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase 1 Clinical |
Shengyan Pharmaceutical Technology, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
Descartes-15 |
Descartes-015; Descartes-15 |
Phase 1 Clinical |
Cartesian Therapeutics Inc |
Solid tumours; Multiple Myeloma; Autoimmune Diseases of the Nervous System |
Details
|
ACLX-001 |
ACLX-001 |
Phase 1 Clinical |
Arcellx Inc |
Multiple Myeloma |
Details
|
CB-011 |
CB-011 |
Phase 1 Clinical |
Caribou Biosciences Inc |
Multiple Myeloma |
Details
|
FT-576 |
FT-576 |
Phase 1 Clinical |
University Of Minnesota, Fate Therapeutics Inc |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
P-BCMA-ALLO1 |
P-BCMA-ALLO1 |
Phase 1 Clinical |
Transposagen Biopharmaceuticals Inc, Janssen Biotech Inc, Poseida Therapeutics Inc |
Multiple Myeloma |
Details
|
BCMA CAR-NK (Hrain Biotechnology) |
HR012 |
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital) |
|
Phase 1 Clinical |
Wuhan Union Hospital |
Lupus Erythematosus, Systemic |
Details
|
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine) |
FKC-288; FKC288 |
Phase 1 Clinical |
Nanjing University School Of Medicine |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Nephritis |
Details
|
C-CAR168 CAR T-cell therapy (AbelZeta) |
C-CAR168 |
Phase 1 Clinical |
AbelZeta Pharma Inc |
Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Muscular Diseases |
Details
|
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) |
BMS-986453 |
Phase 1 Clinical |
Juno Therapeutics Inc |
Multiple Myeloma |
Details
|
SIM-0500 |
SIM-0500; SIM0500 |
Phase 1 Clinical |
Hainan Xiansheng Re Ming Pharmaceutical Co Ltd |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) |
|
Phase 1 Clinical |
Hualan Genetic Engineering (Henan) Co Ltd |
Multiple Myeloma |
Details
|
BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics) |
CBG-002 CAR-T |
Phase 1 Clinical |
Carbiogene Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) |
SWK001; SWK-001 |
Phase 1 Clinical |
Hunan Siweikang Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T (Nanjing Kati Medical Technology) |
|
Phase 1 Clinical |
Nanjing Kati Medical Technology Co Ltd |
Multiple Myeloma |
Details
|
Belantamab |
GSK2857914; GSK-2857914 |
Phase 1 Clinical |
Glaxosmithkline Plc |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) |
|
Phase 1 Clinical |
Eugia Pharma Specialities Ltd, Actavis Inc |
Multiple Myeloma |
Details
|
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) |
|
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
TQB-2934 |
TQB2934; TQB-2934 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Multiple Myeloma |
Details
|
MCARH-125 |
MCARH-125 |
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Multiple Myeloma |
Details
|
ISB-2001 |
ISB-2001 |
Phase 1 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma |
Details
|
OriC-321 |
OriC-321; Ori-C-321 |
Phase 1 Clinical |
Zhejiang University, OriCell Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
HY-027 |
HY-027 |
Phase 1 Clinical |
Juventas Cell Therapy Ltd |
Multiple Myeloma |
Details
|
MEDI-2228 |
MEDI-2228 |
Phase 1 Clinical |
Medimmune Llc |
Multiple Myeloma |
Details
|
IBI-346 |
IBI-346 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-NKE |
BCMA-NKE |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Multiple Myeloma |
Details
|
GR-1803 |
GR-1803 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
MCM-998 |
MCM-998; LXG-250 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
F-182112 |
F-182112; F182112 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA/CD19 CAR-T Therapy(University College London) |
|
Phase 1 Clinical |
University College London |
Multiple Myeloma |
Details
|
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) |
|
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Multiple Myeloma |
Details
|
JWCAR129 |
JWCAR129; JWCAR-129 |
Phase 1 Clinical |
Suzhou Yaomingjunuo Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) |
|
Phase 1 Clinical |
Chongqing Xinqiao Hospital |
Multiple Myeloma |
Details
|
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) |
LCAR-BCX |
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University, Shanghai YaKe Biotechnology Co Ltd |
Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
C-4-29 |
|
Phase 1 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Carcinoma, Renal Cell; Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Multiple Myeloma |
Details
|
spCART-269 |
spCART-269 |
Phase 1 Clinical |
Shanghai Tongji Hospital, Tongji University School Of Medicine |
Multiple Myeloma |
Details
|
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Multiple Myeloma |
Details
|
CC-98633 |
CC-98633 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) |
|
Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Hematologic Neoplasms |
Details
|
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) |
|
Clinical |
Huazhong University Of Science And Technology |
Multiple Myeloma |
Details
|
PD-1Ab21-BCMACAR-T (CD biopharma) |
CD-003; CD-203 |
Clinical |
|
Multiple Myeloma |
Details
|
CT-0590(The First Affiliated Hospital Of Soochow University) |
CT-0590 |
Clinical |
CARsgen Therapeutics Holdings Ltd |
Multiple Myeloma |
Details
|
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) |
|
Clinical |
BRL Medicine Inc |
Multiple Myeloma |
Details
|
BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics) |
UTAA17 |
|
Persongen Biotherapeutics (Suzhou) Co Ltd |
|
Details
|
Autologous BCMA-directed CAR T-cell therapy (The First Affiliated Hospital of Soochow University) |
|
Phase 3 Clinical |
The First Affiliated Hospital Of Soochow University |
Leukemia; Multiple Myeloma |
Details
|
ABBV-383 |
TNB-383B; ABBV-383 |
Phase 3 Clinical |
Teneobio Inc, Abbvie Inc |
Multiple Myeloma |
Details
|
Alnuctamab |
CC-93269; EM-901; BMS-986349 |
Phase 3 Clinical |
Engmab Ag |
Multiple Myeloma |
Details
|
BCMA CAR-T Cells (Pregene) |
PRG-1801 |
Phase 2 Clinical |
Shenzhen Prekin Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anitocabtagene autoleucel |
CART-ddBCMA; Kite-772 |
Phase 2 Clinical |
Arcellx Inc |
Multiple Myeloma |
Details
|
Anti BCMA CAR T cell therapy (Shanghai Hrain Biotechnology) |
BCMA-CART; HR003 |
Phase 2 Clinical |
Hrain Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti BCMA chimeric antigen receptor T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Lymphoma, B-Cell; Multiple Myeloma; Lymphoma, Non-Hodgkin |
Details
|
BCMA CAR-T cell therapy (Chongqing Precision Biotech) |
|
Phase 2 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Plasmacytoma; Multiple Myeloma; Neoplasms, Plasma Cell |
Details
|
C-CAR088 |
C-CAR088 |
Phase 2 Clinical |
|
Multiple Myeloma |
Details
|
Anti-BCMA chimeric antigen receptor T cell therapy (Cartesian) |
Descartes-08 |
Phase 2 Clinical |
Cartesian Therapeutics Inc |
Myasthenia Gravis; Multiple Myeloma; Lupus Erythematosus, Systemic |
Details
|
Orvacabtagene autoleucel |
ET-140; FCARH-143; ET140-CAR; MCARH-171; JCARH-125 |
Phase 2 Clinical |
Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc |
Multiple Myeloma |
Details
|
GC-012F |
GC-012F; GC012F |
Phase 2 Clinical |
Gracell Biotechnologies (Shanghai) Co Ltd |
Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma, Non-Hodgkin |
Details
|
BCMA CAR-NK 92 cell therapy (Asclepius Technology Company Group) |
|
Phase 2 Clinical |
Asclepius Technology Company Group |
Multiple Myeloma |
Details
|
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) |
|
Phase 2 Clinical |
People'S Liberation Army General Hospital Military Service |
Multiple Myeloma |
Details
|
KQ-2003 |
KQ2003; KQ-2003 |
Phase 2 Clinical |
Shanghai Keqi Pharmaceutical Technology Co Ltd |
Solid tumours; Multiple Myeloma; POEMS Syndrome |
Details
|
HDP-101 |
HDP-101; HDP101-ATAC |
Phase 2 Clinical |
Heidelberg |
Paraproteinemias; Multiple Myeloma |
Details
|
REGN-5459 |
REGN-5459 |
Phase 2 Clinical |
|
Multiple Myeloma; Renal Insufficiency, Chronic |
Details
|
Fourth-gen CAR T Cells Targeting BCMA/CD19 therapy(Essen Biotech) |
|
Phase 2 Clinical |
Essen Biotech |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Myositis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Lupus Nephritis; Lupus Erythematosus, Systemic |
Details
|
Anti-BCMA CAR-NK Therapy(Shahid Beheshti University of Medical Sciences) |
|
Phase 2 Clinical |
Shahid Beheshti University Of Medical Sciences |
Multiple Myeloma |
Details
|
IBI-3003 |
IBI3003; IBI-3003 |
Phase 2 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-GPRC5D CAR-T Cells Therapy(Wuhan Union Hospital) |
|
Phase 2 Clinical |
Guangzhou Bio-Gene Technology Co Ltd, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
CART-ASCT-CART2 cells Therapy(Institute Of Hematology & Blood Diseases Hospital) |
|
Phase 2 Clinical |
Institute Of Hematology & Blood Diseases Hospital |
Multiple Myeloma |
Details
|
MBS-314 |
MBS-314 |
Phase 2 Clinical |
Beijing Mabworks Biotech Co Ltd |
Multiple Myeloma |
Details
|
SAR445514 |
SAR445514; SAR-445514; IPH6401/SAR514 |
Phase 2 Clinical |
Sanofi |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
CART-BCMA(Simnova) |
SNC-102(Simnova); SNC102(Simnova) |
Phase 2 Clinical |
Shanghai Simnova Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
CAR-BCMA(Sheba Medical Center) |
|
Phase 2 Clinical |
Sheba Medical Center, Israel |
Multiple Myeloma |
Details
|
Humanized CART Directed Against BCMA |
ARI-0002h |
Phase 2 Clinical |
Instituto De Salud Carlos Iii |
Multiple Myeloma |
Details
|
Descartes-11 |
Descartes-11; Descartes-011 |
Phase 2 Clinical |
Cartesian Therapeutics Inc |
Multiple Myeloma |
Details
|
BCMA CAR-T Cell Therapy (Shenzhen University General Hospital) |
|
Phase 2 Clinical |
Shenzhen University General Hospital |
Multiple Myeloma |
Details
|
CM-336(Connaught Biomedical Technology) |
CM-336 |
Phase 2 Clinical |
Keymed Biosciences Co Ltd |
Multiple Myeloma |
Details
|
PHE-885 |
PHE-885 |
Phase 2 Clinical |
Novartis Pharma Ag |
Hematologic Neoplasms; Multiple Myeloma |
Details
|
ALLO-605 |
ALLO-605; ALLO605 |
Phase 2 Clinical |
Cellectis Sa |
Multiple Myeloma |
Details
|
EMB-06 |
EMB-06; EMB06 |
Phase 2 Clinical |
Shanghai Epimab Biotherapeutics, Inc |
Multiple Myeloma |
Details
|
NXC-201 |
HBI-0101; NXC-201 |
Phase 2 Clinical |
Immix Biopharma Inc, Hadassah Medical Organization |
Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma |
Details
|
BCMA Targeted CAR-T Cell Therapy (Yake Biotechnology) |
|
Phase 2 Clinical |
Shanghai YaKe Biotechnology Co Ltd |
Neoplasms; Multiple Myeloma |
Details
|
BCMA TriTAC |
HPN-217 |
Phase 1 Clinical |
Harpoon Therapeutics, Abbvie Inc |
Multiple Myeloma |
Details
|
ACTR 087/SEA BCMA combination therapy |
|
Phase 1 Clinical |
Unum Therapeutics Inc |
Multiple Myeloma |
Details
|
Motacabtagene lurevgedleucel |
CTX-120 |
Phase 1 Clinical |
Crispr Therapeutics Ag |
Multiple Myeloma |
Details
|
AUTO-2 |
AUTO-2; SUB-96123 |
Phase 1 Clinical |
Autolus |
Multiple Myeloma |
Details
|
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) |
|
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
POEMS Syndrome |
Details
|
bb-21217 |
bb-21217 |
Phase 1 Clinical |
Bluebird Bio Inc, Bristol-Myers Squibb Company |
Multiple Myeloma |
Details
|
AMG-224 |
AMG-224 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
Ispectamab debotansine |
CC-99712; BMS-986352; SP-8919 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
WVT-078(Novartis Pharma) |
WVT-078 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
Pacanalotamab |
AMG-420; BI-836909 |
Phase 1 Clinical |
Micromet Inc |
Multiple Myeloma |
Details
|
ALLO-715 |
ALLO-715 |
Phase 1 Clinical |
Cellectis Sa |
Multiple Myeloma |
Details
|
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) |
|
Phase 1 Clinical |
The First Affiliated Hospital Of Nanchang University |
Multiple Myeloma |
Details
|
Pavurutamab |
AMG-701 |
Phase 1 Clinical |
Amgen Inc |
Multiple Myeloma |
Details
|
CART-BCMA |
MTV-273; CART-BCMA |
Phase 1 Clinical |
University Of Pennsylvania |
Rejection of renal transplantation; Renal Insufficiency; Multiple Myeloma; Kidney Failure, Chronic |
Details
|
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) |
|
Phase 1 Clinical |
Icell Gene Therapeutics (Int'L) Ltd |
Multiple Myeloma; Lupus Erythematosus, Systemic; Waldenstrom Macroglobulinemia |
Details
|
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) |
|
Phase 1 Clinical |
Shengyan Pharmaceutical Technology, Wuhan Union Hospital |
Multiple Myeloma |
Details
|
Descartes-15 |
Descartes-015; Descartes-15 |
Phase 1 Clinical |
Cartesian Therapeutics Inc |
Solid tumours; Multiple Myeloma; Autoimmune Diseases of the Nervous System |
Details
|
ACLX-001 |
ACLX-001 |
Phase 1 Clinical |
Arcellx Inc |
Multiple Myeloma |
Details
|
CB-011 |
CB-011 |
Phase 1 Clinical |
Caribou Biosciences Inc |
Multiple Myeloma |
Details
|
FT-576 |
FT-576 |
Phase 1 Clinical |
University Of Minnesota, Fate Therapeutics Inc |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
P-BCMA-ALLO1 |
P-BCMA-ALLO1 |
Phase 1 Clinical |
Transposagen Biopharmaceuticals Inc, Janssen Biotech Inc, Poseida Therapeutics Inc |
Multiple Myeloma |
Details
|
BCMA CAR-NK (Hrain Biotechnology) |
HR012 |
Phase 1 Clinical |
Hrain Biotechnology Co Ltd |
Leukemia, Plasma Cell; Multiple Myeloma |
Details
|
CD19/BCMA Hi-TCR-T cell therapy(Wuhan Union Hospital) |
|
Phase 1 Clinical |
Wuhan Union Hospital |
Lupus Erythematosus, Systemic |
Details
|
The autologous dual target BCMA/CD19-CAR-T cell therapy(Nanjing University School Of Medicine) |
FKC-288; FKC288 |
Phase 1 Clinical |
Nanjing University School Of Medicine |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Lupus Nephritis |
Details
|
C-CAR168 CAR T-cell therapy (AbelZeta) |
C-CAR168 |
Phase 1 Clinical |
AbelZeta Pharma Inc |
Multiple Sclerosis, Relapsing-Remitting; Autoimmune Diseases; Neuromyelitis Optica; Lupus Erythematosus, Systemic; Muscular Diseases |
Details
|
BCMAxGPRC5D CAR-T therapy (Juno Therapeutics) |
BMS-986453 |
Phase 1 Clinical |
Juno Therapeutics Inc |
Multiple Myeloma |
Details
|
SIM-0500 |
SIM-0500; SIM0500 |
Phase 1 Clinical |
Hainan Xiansheng Re Ming Pharmaceutical Co Ltd |
Bone Marrow Neoplasms; Multiple Myeloma |
Details
|
Recombinant anti BCMA/CD3 bispecific antibody(Hualan Genetic Engineering) |
|
Phase 1 Clinical |
Hualan Genetic Engineering (Henan) Co Ltd |
Multiple Myeloma |
Details
|
BCMA Targeted CAR-T Cell Therapy (Carbiogene Therapeutics) |
CBG-002 CAR-T |
Phase 1 Clinical |
Carbiogene Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
BCMA-CD19 CAR T cell therapy (Hunan Siweikang Pharma) |
SWK001; SWK-001 |
Phase 1 Clinical |
Hunan Siweikang Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T (Nanjing Kati Medical Technology) |
|
Phase 1 Clinical |
Nanjing Kati Medical Technology Co Ltd |
Multiple Myeloma |
Details
|
Belantamab |
GSK2857914; GSK-2857914 |
Phase 1 Clinical |
Glaxosmithkline Plc |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T-cell therapy (Actavis/Eugia Pharma) |
|
Phase 1 Clinical |
Eugia Pharma Specialities Ltd, Actavis Inc |
Multiple Myeloma |
Details
|
LUCAR-B68 cells Therapy(Nanjing Legend Biotech Co) |
|
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
TQB-2934 |
TQB2934; TQB-2934 |
Phase 1 Clinical |
Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group |
Multiple Myeloma |
Details
|
MCARH-125 |
MCARH-125 |
Phase 1 Clinical |
Memorial Sloan Kettering Cancer Center |
Multiple Myeloma |
Details
|
ISB-2001 |
ISB-2001 |
Phase 1 Clinical |
Ichnos Sciences Sa |
Multiple Myeloma |
Details
|
OriC-321 |
OriC-321; Ori-C-321 |
Phase 1 Clinical |
Zhejiang University, OriCell Therapeutics Co Ltd |
Multiple Myeloma |
Details
|
HY-027 |
HY-027 |
Phase 1 Clinical |
Juventas Cell Therapy Ltd |
Multiple Myeloma |
Details
|
MEDI-2228 |
MEDI-2228 |
Phase 1 Clinical |
Medimmune Llc |
Multiple Myeloma |
Details
|
IBI-346 |
IBI-346 |
Phase 1 Clinical |
Innovent Biologics(Suzhou) Co Ltd |
Multiple Myeloma |
Details
|
BCMA-NKE |
BCMA-NKE |
Phase 1 Clinical |
Bristol-Myers Squibb Company |
Multiple Myeloma |
Details
|
GR-1803 |
GR-1803 |
Phase 1 Clinical |
Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
MCM-998 |
MCM-998; LXG-250 |
Phase 1 Clinical |
Novartis Pharma Ag |
Multiple Myeloma |
Details
|
F-182112 |
F-182112; F182112 |
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA/CD19 CAR-T Therapy(University College London) |
|
Phase 1 Clinical |
University College London |
Multiple Myeloma |
Details
|
Recombinant humanized anti-BCMA/CD3 bispecific antibody(New Time Pharmaceutical) |
|
Phase 1 Clinical |
Shandong New Time Pharmaceutical Co Ltd |
Multiple Myeloma |
Details
|
CXCR4 modified anti-BCMA CAR T cell therapy (Sichuan University) |
|
Phase 1 Clinical |
Sichuan University |
Multiple Myeloma |
Details
|
JWCAR129 |
JWCAR129; JWCAR-129 |
Phase 1 Clinical |
Suzhou Yaomingjunuo Biotechnology Co Ltd |
Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (Xinqiao Hospital) |
|
Phase 1 Clinical |
Chongqing Xinqiao Hospital |
Multiple Myeloma |
Details
|
BCMA-targeted universal LCAR-BCX cell therapy (Nanjing Legend Biotech) |
LCAR-BCX |
Phase 1 Clinical |
|
Multiple Myeloma |
Details
|
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) |
|
Phase 1 Clinical |
Zhejiang University, Shanghai YaKe Biotechnology Co Ltd |
Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin |
Details
|
C-4-29 |
|
Phase 1 Clinical |
Chongqing Precision Biotechnology Co Ltd |
Carcinoma, Renal Cell; Multiple Myeloma |
Details
|
Anti-BCMA CAR-T cell therapy (PersonGen Biomedicine) |
|
Phase 1 Clinical |
Persongen Biotherapeutics |
Multiple Myeloma |
Details
|
spCART-269 |
spCART-269 |
Phase 1 Clinical |
Shanghai Tongji Hospital, Tongji University School Of Medicine |
Multiple Myeloma |
Details
|
BCMA CAR-T cell therapy (Hebei Senlang Biotechnology) |
|
Phase 1 Clinical |
Hebei Senlang Biological Technology Co Ltd |
Multiple Myeloma |
Details
|
CC-98633 |
CC-98633 |
Phase 1 Clinical |
Celgene Corp |
Multiple Myeloma |
Details
|
Anti-BCMA CAR T cell therapy (Wuhan Bio-Raid Biotechnology) |
|
Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Hematologic Neoplasms |
Details
|
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) |
|
Clinical |
Huazhong University Of Science And Technology |
Multiple Myeloma |
Details
|
PD-1Ab21-BCMACAR-T (CD biopharma) |
CD-003; CD-203 |
Clinical |
|
Multiple Myeloma |
Details
|
CT-0590(The First Affiliated Hospital Of Soochow University) |
CT-0590 |
Clinical |
CARsgen Therapeutics Holdings Ltd |
Multiple Myeloma |
Details
|
BCMA-UCART cell therapy (Shanghai Bioray Laboratory) |
|
Clinical |
BRL Medicine Inc |
Multiple Myeloma |
Details
|
BCMA targeting UCAR-T cell therapy (PersonGen BioTherapeutics) |
UTAA17 |
|
Persongen Biotherapeutics (Suzhou) Co Ltd |
|
Details
|